Millennium Management’s Protalix BioTherapeutics PLX Stock Holding History

Millennium Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-963,011	Closed	-$2.47M	–	6229
2025 Q1	$2.47M	Buy	963,011 +575,090	+148%	+$1.37M	﹤0.01%	3581
2024 Q4	$729K	Buy	387,921 +14,164	+4%	+$20K	﹤0.01%	4453
2024 Q3	$381K	Sell	373,757 -437,403	-54%	-$460K	﹤0.01%	5036
2024 Q2	$949K	Buy	811,160 +800,676	+7,637%	+$946K	﹤0.01%	4144
2024 Q1	$13.2K	Buy	+10,484	New	+$15.7K	﹤0.01%	5881
2023 Q3	–	Sell	-21,232	Closed	-$42.5K	–	6455
2023 Q2	$42.5K	Sell	21,232 -65,466	-76%	-$156K	﹤0.01%	5505
2023 Q1	$182K	Buy	+86,698	New	+$152K	﹤0.01%	5209
2022 Q3	–	Sell	-19,223	Closed	-$21K	–	7396
2022 Q2	$21K	Buy	+19,223	New	+$22.5K	﹤0.01%	6474
2017 Q1	–	Sell	-11,010	Closed	-$49K	–	3768
2016 Q4	$49K	Buy	+11,010	New	+$49.2K	﹤0.01%	3254
2013 Q4	–	Sell	-3,439	Closed	-$156K	–	3706
2013 Q3	$156K	Buy	3,439 +1,734	+102%	+$89K	﹤0.01%	3147
2013 Q2	$84K	Buy	+1,705	New	+$90.5K	﹤0.01%	2881

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management's PLX Position: Q2 2025 in Review

Millennium Management sold out of Protalix BioTherapeutics (PLX) in Q2 2025, closing a stake of 963,011 shares — an estimated $2.47M sold.

Millennium Management first reported a position in PLX in Q2 2013 and held it in 11 quarters. The position peaked at $2.47M in Q1 2025. 63 funds tracked by Wall St. Rank hold PLX as of Q2 2025.

Millennium Management reported no remaining Protalix BioTherapeutics position as of Q2 2025 after selling out during the quarter.
Millennium Management sold 963,011 Protalix BioTherapeutics shares in Q2 2025, an estimated $2.47M.
Millennium Management first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 11 quarters.
Millennium Management's Protalix BioTherapeutics position peaked at $2.47M in Q1 2025.
63 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2025.

Based on Millennium Management's 13F filing for Q2 2025, filed 14 Aug 2025.